Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 20-year-old male is unsure how to interpret his bloodwork results and whether he should take finasteride for hair loss. His bloodwork shows borderline high levels of albumin and testosterone, and high progesterone, but normal levels of other hormones.

Creatine use may lead to increased hair thinning, especially for those genetically prone to hair loss, prompting some users to stop its use. Topical finasteride is used to manage hair loss, but concerns remain about creatine's impact on hair density.

The conversation discusses concerns about using cordyceps while on dutasteride due to potential DHT increase, with OP experiencing hair loss after using creatine. OP is advised to stop creatine and give dutasteride more time to evaluate its effectiveness.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

Creatine may increase DHT levels, potentially accelerating hair loss in those predisposed. Some users suggest using finasteride or dutasteride to counteract this effect.

Minoxidil regrowth may be slowed by low vitamin D and ferritin levels. The user is experiencing slow hair regrowth and is considering addressing these deficiencies.

The conversation is about a 19-year-old female experiencing hair loss, potentially due to deficiencies in iron, ferritin, and vitamin D. She is considering iron and vitamin D supplementation and exploring dietary changes, while also planning to consult a dermatologist when possible.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

Alfatradiol is used by some for hair loss, often alongside treatments like finasteride, RU58841, and minoxidil, but its effectiveness is unclear. Some users report no significant improvement, while others note reduced sebum production but experience side effects like gallbladder pain.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

A dermatologist checked for hereditary hair loss using blood tests and plans to perform a trichogram. The user had slightly low Vitamin D3 levels, and the trichogram may help confirm androgenetic alopecia.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Creatine generally does not affect hair loss, but some report increased shedding due to higher DHT levels. Many manage hair loss with dutasteride, finasteride, and minoxidil.

Elevated bile acids can inhibit the enzyme AKR1C2, leading to increased DHT levels, which may accelerate hair loss in those predisposed to androgenetic alopecia. Treatments mentioned include topical minoxidil and finasteride.

Some users have experienced good hair regrowth with estradiol, cyproterone acetate, spironolactone, and bicalutamide, but these treatments may cause feminization and other side effects. It's advised to consult a doctor before using these treatments, as they can lower testosterone and have significant risks.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.

The conversation discusses the effectiveness and value of a Locklabs pill containing finasteride, minoxidil, biotin, and a low dose of dutasteride for hair loss. The user is uncertain if the .1mg dutasteride dosage is sufficient and worth the cost.

The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.

Creatine may be linked to hair loss, possibly due to contamination with steroids. Users suggest avoiding creatine if it causes hair loss, as mislabeled products could be the issue.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

The conversation discusses hair loss and bloodwork results, focusing on zinc, vitamin D, and ferritin levels. The user is experiencing telogen effluvium after surgery and seeks advice on supplementation.

GHK-Cu helped control Seborrheic Dermatitis and reduced scalp irritation, with no immediate change in hair fall or growth. Users reported reduced flakes and healthier skin using GHK-Cu topically.

Check ferritin, thyroid, and vitamin D levels before spending on hair loss treatments. Addressing deficiencies can slow hair shedding and save money.